NCT03616860View on ClinicalTrials.gov

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Glioblastoma
Interventions
DEVICE

Focused Ultrasound (FUS) BBB Disruption

FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT03616860 - Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma | Biotech Hunter | Biotech Hunter